Prophylaxis of hereditary breast cancer.
作者信息
de Groot Jolien S, van Diest Paul J, Derksen Patrick W B
机构信息
Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Currently Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
出版信息
Aging (Albany NY). 2017 Dec 8;9(12):2453-2454. doi: 10.18632/aging.101342.
Abstract
摘要
相似文献
1
Prophylaxis of hereditary breast cancer.
Aging (Albany NY). 2017 Dec 8;9(12):2453-2454. doi: 10.18632/aging.101342.
2
Intraductal therapy for the prevention of breast cancer.
Curr Opin Investig Drugs. 2010 Jun;11(6):646-52.
3
Pharmacoprevention for hereditary breast and ovarian cancer.
Minerva Ginecol. 2016 Oct;68(5):517-35. Epub 2016 Feb 29.
4
Intraductal Therapy in Breast Cancer: Current Status and Future Prospective.
J Mammary Gland Biol Neoplasia. 2020 Jun;25(2):133-143. doi: 10.1007/s10911-020-09453-4. Epub 2020 Jun 23.
5
Sounding Board. The problem of breast-cancer prophylaxis.
N Engl J Med. 1975 Nov 20;293(21):1095-8. doi: 10.1056/NEJM197511202932111.
6
Breast cancer (3).
N Engl J Med. 1992 Aug 13;327(7):473-80. doi: 10.1056/NEJM199208133270706.
7
Chemoprevention of breast and colon cancer.
Curr Oncol Rep. 2000 May;2(3):223-4. doi: 10.1007/s11912-000-0071-3.
8
Breast cancer drugs should be offered to healthy but high risk women, US panel concludes.
BMJ. 2013 Apr 18;346:f2499. doi: 10.1136/bmj.f2499.
9
Targeting early stage DCIS breast cancer directly in the ducts with intraductal chemotherapy.
Cancer Biol Ther. 2006 Mar;5(3):249-50.
10
The Japanese Breast Cancer Society clinical practice guideline for epidemiology and prevention of breast cancer.
Breast Cancer. 2015 Jan;22(1):16-27. doi: 10.1007/s12282-014-0555-x. Epub 2014 Aug 2.
本文引用的文献
1
Intraductal cisplatin treatment in a -associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.
Oncotarget. 2017 Jun 15;8(37):60750-60763. doi: 10.18632/oncotarget.18490. eCollection 2017 Sep 22.
2
A feasibility study of the intraductal administration of chemotherapy.
Cancer Prev Res (Phila). 2013 Jan;6(1):51-8. doi: 10.1158/1940-6207.CAPR-12-0228. Epub 2012 Nov 20.
3
Preclinical and clinical evaluation of intraductally administered agents in early breast cancer.
Sci Transl Med. 2011 Oct 26;3(106):106ra108. doi: 10.1126/scitranslmed.3002368.
4
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
BMC Clin Pharmacol. 2008 Sep 17;8:7. doi: 10.1186/1472-6904-8-7.
5
Ductal access for prevention and therapy of mammary tumors.
Cancer Res. 2006 Jan 15;66(2):638-45. doi: 10.1158/0008-5472.CAN-05-4329.
6
Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution.
Cancer Chemother Pharmacol. 1991;27(5):347-53. doi: 10.1007/BF00688856.
Zotero 插件